These results implicate loss of TGF-β signaling proteins in human hepatocellular cancer and cirrhosis, and suggest that VD may serve as a candidate treatment reagent to restore the lost TGF-β signaling in these patients. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.